Taral Patel, MD
OncologistMid Ohio Oncology Hematology Inc.
Taral Patel, MD, is an Oncologist in private practice with Mid Ohio Oncology-Hematology, Inc. He treats patients with both cancer and blood disorders. Dr. Patel has been a principal investigator for multiple clinical trials in colon cancer, lung cancer, lymphoma, and growth factor. He has been on the advisory board for several drug companies including Amgen, Novartis, Lilly, Genetech, and Aventis. (This is me - Update Profile)
| 1999 - present | Oncologist Mid Ohio Oncology Hematology Inc. |
|---|
GLG Study Groups with Taral Patel, MD(?)
| Study Group Name | Members |
|---|---|
| Multiple Myeloma Physicians | 179 |
| Breast Oncologists (US) | 317 |
| GI Cancer Oncologists (US) | 84 |
| Lung Cancer Oncologists (US) | 115 |
GLG NewsSM
Analyses by Taral Patel, MD(?)
New data with low and high dose of Avastin with Taxoter
esults showed that PROVENGE patients experienced improved survival if they received more cells across the three doses of PROVENGE (higher cumulative TNC count (p=0.019)) or higher cumulative CD54 upregulation values (p=0.009). The effect on survival for TNCs appeared to reflect in part the patients'...
“On face value the data look very good,” said Buzdar, who voted with the slim (5-4) majority against the drug. In the study that was the basis of Genentech’s application, Avastin appeared to slow the progress of the disease. advanced breast cancer who had already tried other drugs. He said he’s never...
CMS is doing right thing. This will aviod pt fall and bedsore during hospitalzation
GLG InstituteSM Seminars with Taral Patel, MD(?)
View all GLG InstituteSM Seminars in Healthcare
Request a project with Taral Patel, MD
Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms